JP2002513397A - エンドセリン拮抗薬:n−〔〔2’−〔〔(4,5−ジメチル−3−イソキサゾリル)アミノ〕スルホニル〕−4−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−イル〕メチル〕−n,3,3−トリメチルブタンアミドおよびn−(4,5−ジメチル−3−イソキサゾリル)−2’−〔(3,3−ジメチル−2−オキソ−1−ピロリジニル)メチル〕−4’−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−スルホンアミドおよびそれらの塩 - Google Patents
エンドセリン拮抗薬:n−〔〔2’−〔〔(4,5−ジメチル−3−イソキサゾリル)アミノ〕スルホニル〕−4−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−イル〕メチル〕−n,3,3−トリメチルブタンアミドおよびn−(4,5−ジメチル−3−イソキサゾリル)−2’−〔(3,3−ジメチル−2−オキソ−1−ピロリジニル)メチル〕−4’−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−スルホンアミドおよびそれらの塩Info
- Publication number
- JP2002513397A JP2002513397A JP53299998A JP53299998A JP2002513397A JP 2002513397 A JP2002513397 A JP 2002513397A JP 53299998 A JP53299998 A JP 53299998A JP 53299998 A JP53299998 A JP 53299998A JP 2002513397 A JP2002513397 A JP 2002513397A
- Authority
- JP
- Japan
- Prior art keywords
- treating
- compound
- administering
- dimethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.N−[[2'−[[(4,5−ジメチル−3−イソキサゾリル)アミノ]ス ルホニル]−4−(2−オキサゾリル)[1,1'−ビフェニル]−2−イル]メ チル]−N,3,3−トリメチルブタンアミドまたはその塩である化合物。 2.N−[[2'−[[(4,5−ジメチル−3−イソキサゾリル)アミノ]ス ルホニル]−4−(2−オキサゾリル)[1,1'−ビフェニル]−2−イル]メ チル]−N,3,3−トリメチルブタンアミドまたはその医薬的に許容しうる塩で ある請求の範囲1に記載の化合物。 3.N−[[2'−[[(4,5−ジメチル−3−イソキサゾリル)アミノ]ス ルホニル]−4−(2−オキサゾリル)[1,1'−ビフェニル]−2−イル]メ チル]−N,3,3−トリメチルブタンアミドである請求の範囲1に記載の化合物 。 4.化合物の医薬的に許容しうる塩であって、該塩がリチウム、ナトリウムも しくはカリウム塩、または有機アミン塩基によって形成される塩である請求の範 囲1に記載の化合物。 5.哺乳動物のエンドセリン−関連障害を処置する方法であって、該哺乳動物 に対して、エンドセリン−関連障害の処置に有効量の請求の範囲2に記載の化合 物を投与することから成る方法。 6.高血圧症を処置する方法であって、高血圧症の処置に有効量の請求の範囲 2に記載の化合物を投与することから成る方法。 7.肺動脈高血圧症を処置する方法であって、肺動脈高血圧症の処置に有効量 の請求の範囲2に記載の化合物を投与することから成る方法。 8.一次肺動脈高血圧症を処置する方法であって、一次肺動脈高血圧症の処置 に有効量の請求の範囲2に記載の化合物を投与することから成る方法。 9.良性前立腺肥大を処置する方法であって、良性前立腺肥大の処置に有効量 の請求の範囲2に記載の化合物を投与することから成る方法。 10.片頭痛を処置する方法であって、片頭痛の処置に有効量の請求の範囲2 に記載の化合物を投与することから成る方法。 11.腎、糸球体または糸球体間質細胞障害を処置する方法であって、腎、糸 球体または糸球体間質細胞障害の処置に有効量の請求の範囲2に記載の化合物を 投与することから成る方法。 12.内毒血症を処置する方法であって、内毒血症の処置に有効量の請求の範 囲2に記載の化合物を投与することから成る方法。 13.虚血を処置する方法であって、虚血の処置に有効量の請求の範囲2に記 載の化合物を投与することから成る方法。 14.アテローム性動脈硬化を処置する方法であって、アテローム性動脈硬化 の処置に有効量の請求の範囲2に記載の化合物を投与することから成る方法。 15.再狭窄を処置する方法であって、再狭窄の処置に有効量の請求の範囲2 に記載の化合物を投与することから成る方法。 16.クモ膜下出血を処置する方法であって、クモ膜下出血の処置に有効量の 請求の範囲2に記載の化合物を投与することから成る方法。 17.うっ血性心不全を処置する方法であって、うっ血性心不全の処置に有効 量の請求の範囲2に記載の化合物を投与することから成る方法。 18.請求の範囲2に記載の化合物の投与を、アンギオテンシンII(AII)レ セプタ拮抗薬、レニン・インヒビター、アンギオテンシン変換酵素(ACE)イ ンヒビター、二元中性エンドペプチダーゼ(NEP)−ACEインヒビター、利 尿薬または強心薬グリコシドの少なくとも1種の投与の前、同時または後に行な う請求の範囲5に記載の方法。 19.エンドセリン−関連障害の処置用医薬組成物であって、該処置に有効量 の請求の範囲2に記載の化合物および生理学的に許容しうるビヒクルまたは担体 から成る医薬組成物。 20.さらにアンギオテンシンII(AII)レセプタ拮抗薬、レニン・インヒビ ター、アンギオテンシン変換酵素(ACE)インヒビター、二元中性エンドペプ チダーゼ(NEP)−ACEインヒビター、利尿薬または強心薬グリコシドの少 なくとも1種を含有する請求の範囲19に記載の医薬組成物。 21.N−(4,5−ジメチル−3−イソキサゾリル)−2'−ホルミル−N− [(2−メトキシエトキシ)メチル]−4'−(2−オキサゾリル)[1,1'− ビフェニル]−2−スルホンアミドである化合物。 22.N−(4,5−ジメチル−3−イソキサゾリル)−2'−ホルミル−4' −(2−オキサゾリル)[1,1'−ビフェニル]−2−スルホンアミドである化 合物。 23.N−(4,5−ジメチル−3−イソキサゾリル)−2'−[(メチルアミ ノ)メチル]−4'−(2−オキサゾリル)[1,1'−ビフェニル]−2−スル ホンアミドである化合物。 24.N−(4,5−ジメチル−3−イソキサゾリル)−2'−[(3,3−ジ メチル−2−オキソ−1−ピロリジニル)メチル]−4'−(2−オキサゾリル )[1,1'−ビフェニル]−2−スルホンアミドまたはその塩である化合物。 25.N−(4,5−ジメチル−3−イソキサゾリル)−2'−[(3,3−ジ メチル−2−オキソ−1−ピロリジニル)メチル]−4'−(2−オキサゾリル )[1,1'−ビフェニル]−2−スルホンアミドまたはその医薬的に許容しうる 塩である請求の範囲24に記載の化合物。 26.N−(4,5−ジメチル−3−イソキサゾリル)−2'−[(3,3−ジ メチル−2−オキソ−1−ピロリジニル)メチル]−4'−(2−オキサゾリル )[1,1'−ビフェニル]−2−スルホンアミドである請求の範囲24に記載の 化合物。 27.化合物の医薬的に許容しうる塩であって、該塩がリチウム、ナトリウム もしくはカリウム塩または有機アミン塩基によって形成される塩である請求の範 囲24に記載の化合物。 28.哺乳動物のエンドセリン−関連障害を処置する方法であって、該哺乳動 物に対して、エンドセリン−関連障害の処置に有効量の請求の範囲25に記載の 化合物を投与することから成る方法。 29.高血圧症を処置する方法であって、高血圧症の処置に有効量の請求の範 囲25に記載の化合物を投与することから成る方法。 30.肺動脈高血圧症を処置する方法であって、肺動脈高血圧症の処置に有効 量の請求の範囲25に記載の化合物を投与することから成る方法。 31.一次肺動脈高血圧症を処置する方法であって、一次肺動脈高血圧症の処 置に有効量の請求の範囲25に記載の化合物を投与することから成る方法。 32.良性前立腺肥大を処置する方法であって、良性前立腺肥大の処置に有効 量の請求の範囲25に記載の化合物を投与することから成る方法。 33.片頭痛を処置する方法であって、片頭痛の処置に有効量の請求の範囲2 5に記載の化合物を投与することから成る方法。 34.腎、糸球体または糸球体間質細胞障害を処置する方法であって、腎、糸 球体または糸球体間質細胞障害の処置に有効量の請求の範囲25に記載の化合物 を投与することから成る方法。 35.内毒血症を処置する方法であって、内毒血症の処置に有効量の請求の範 囲25に記載の化合物を投与することから成る方法。 36.虚血を処置する方法であって、虚血の処置に有効量の請求の範囲25に 記載の化合物を投与することから成る方法。 37.アテローム性動脈硬化を処置する方法であって、アテローム性動脈硬化 の処置に有効量の請求の範囲25に記載の化合物を投与することから成る方法。 38.再狭窄を処置する方法であって、再狭窄の処置に有効量の請求の範囲2 5に記載の化合物を投与することから成る方法。 39.クモ膜下出血を処置する方法であって、クモ膜下出血の処置に有効量の 請求の範囲25に記載の化合物を投与することから成る方法。 40.うっ血性心不全を処置する方法であって、うっ血性心不全の処置に有効 量の請求の範囲25に記載の化合物を投与することから成る方法。 41.請求の範囲25に記載の化合物の投与を、アンギオテンシンII(AII) レセプタ拮抗薬、レニン・インヒビター、アンギオテンシン変換酵素(ACE) インヒビター、二元中性エンドペプチダーゼ(NEP)−ACEインヒビター、 利尿薬または強心薬グリコシドの少なくとも1種の投与の前、同時または後に行 なう請求の範囲28に記載の方法。 42.エンドセリン−関連障害の処置用医薬組成物であって、該処置に有効量 の請求の範囲25に記載の化合物および生理学的に許容しうるビヒクルまたは担 体から成る医薬組成物。 43.さらにアンギオテンシンII(AII)レセプタ拮抗薬、レニン・インヒビ ター、アンギオテンシン変換酵素(ACE)インヒビター、二元中性エンドペプ チダーゼ(NEP)−ACEインヒビター、利尿薬または強心薬グリコシドの少 なくとも1種を含有する請求の範囲42に記載の医薬組成物。 44.N−(4,5−ジメチル−3−イソキサゾリル)−2'−(ヒドロキシメ チル)−N−[(2−メトキシエトキシ)メチル]−4'−(2−オキサゾリル )[1,1'−ビフェニル]−2−スルホンアミドである化合物。 45.2'−(ブロモメチル)−N−(4,5−ジメチル−3−イソキサゾリル )−N−[(2−メトキシエトキシ)メチル]−4'−(2−オキサゾリル)[ 1,1'−ビフェニル]−2−スルホンアミドである化合物。 46.N−(4,5−ジメチル−3−イソキサゾリル)−2'−[(3,3−ジ メチル−2−オキソ−1−ピロリジニル)メチル]−N−[(2−メトキシエト キシ)メチル]−4'−(2−オキサゾリル)[1,1'−ビフェニル]−2−ス ルホンアミドである化合物。 47.4−[[[2'−[[(4,5−ジメチル−3−イソキサゾリル)アミノ ]スルホニル]−4−(2−オキサゾリル)[1,1'−ビフェニル]−2−イル ]メチル]アミノ]−2,2−ジメチルブタン酸である化合物。 48.ぜん息を処置する方法であって、抗ぜん息有効量の請求の範囲2に記載 の化合物を投与することから成る方法。 49.ぜん息を処置する方法であって、抗ぜん息有効量の請求の範囲25に記 載の化合物を投与することから成る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3583297P | 1997-01-30 | 1997-01-30 | |
US60/035,832 | 1997-01-30 | ||
PCT/US1998/001490 WO1998033780A1 (en) | 1997-01-30 | 1998-01-26 | Endothelin antagonists: n-[[2'-[ [(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl]methyl] -n,3,3-trimethylbutanamide and n-(4,5-dimethyl-3-isoxazolyl) -2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl) methyl] -4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide and salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002513397A true JP2002513397A (ja) | 2002-05-08 |
Family
ID=21885049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53299998A Ceased JP2002513397A (ja) | 1997-01-30 | 1998-01-26 | エンドセリン拮抗薬:n−〔〔2’−〔〔(4,5−ジメチル−3−イソキサゾリル)アミノ〕スルホニル〕−4−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−イル〕メチル〕−n,3,3−トリメチルブタンアミドおよびn−(4,5−ジメチル−3−イソキサゾリル)−2’−〔(3,3−ジメチル−2−オキソ−1−ピロリジニル)メチル〕−4’−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−スルホンアミドおよびそれらの塩 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6043265A (ja) |
EP (1) | EP0996618B1 (ja) |
JP (1) | JP2002513397A (ja) |
KR (1) | KR20000070584A (ja) |
CN (1) | CN1117738C (ja) |
AR (1) | AR015358A1 (ja) |
AT (1) | ATE254115T1 (ja) |
AU (1) | AU730111B2 (ja) |
BR (1) | BR9807098A (ja) |
CA (1) | CA2279178A1 (ja) |
CZ (1) | CZ236299A3 (ja) |
DE (1) | DE69819729T2 (ja) |
ES (1) | ES2205451T3 (ja) |
HU (1) | HUP0001310A3 (ja) |
IL (1) | IL130622A (ja) |
NO (1) | NO313142B1 (ja) |
NZ (1) | NZ336380A (ja) |
PL (1) | PL334773A1 (ja) |
RU (1) | RU2183632C2 (ja) |
TW (1) | TW536540B (ja) |
WO (1) | WO1998033780A1 (ja) |
ZA (1) | ZA98759B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016504286A (ja) * | 2012-11-14 | 2016-02-12 | バイアル−ポルテラ アンド シーエー,エス.エー. | 肺動脈高血圧症及び肺障害の治療に使用するための1,3‐ジヒドロイミダゾール‐2‐チオン誘導体 |
WO2022270487A1 (ja) * | 2021-06-22 | 2022-12-29 | 株式会社アークメディスン | 化合物、エンドセリンa受容体拮抗剤及び医薬組成物 |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
EE04156B1 (et) | 1997-04-28 | 2003-10-15 | Texas Biotechnology Corporation | Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
KR100572080B1 (ko) | 1997-10-17 | 2006-04-17 | 유로진 리미티드 | 레닌-안지오텐신계 억제제의 용도 |
WO1999047138A1 (en) * | 1998-03-17 | 1999-09-23 | Warner-Lambert Company | Statin-matrix metalloproteinase inhibitor combinations |
US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EP1237888B1 (en) * | 1999-12-15 | 2006-09-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
AU2464301A (en) | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US6639082B2 (en) * | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
US6573285B2 (en) * | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
US20030040534A1 (en) * | 2001-04-16 | 2003-02-27 | Hughes David E. | Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide |
GEP20074098B (en) | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
EP1572892A4 (en) * | 2001-10-18 | 2007-08-22 | Bristol Myers Squibb Co | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
US7772433B2 (en) * | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US7435824B2 (en) * | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US20040009972A1 (en) * | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
WO2004021997A2 (en) * | 2002-09-06 | 2004-03-18 | Microbia, Inc. | Inhibitors of fungal invasion |
ATE469645T1 (de) * | 2002-10-23 | 2010-06-15 | Bristol Myers Squibb Co | Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
EP1567487A4 (en) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
WO2004066929A2 (en) * | 2003-01-24 | 2004-08-12 | Bristol-Myers Squibb Company | Cycloalkyl containing anilide ligands for the thyroid receptor |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
US7557143B2 (en) * | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
US6846836B2 (en) * | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US7429611B2 (en) | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7754755B2 (en) * | 2004-09-23 | 2010-07-13 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
US8143425B2 (en) * | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US20060128726A1 (en) * | 2004-11-24 | 2006-06-15 | Xuebao Wang | Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7368458B2 (en) * | 2005-01-12 | 2008-05-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) * | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7361766B2 (en) | 2005-01-12 | 2008-04-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006078621A2 (en) * | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
EP1846410B1 (en) * | 2005-02-10 | 2009-01-21 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
AU2006249869A1 (en) * | 2005-05-26 | 2006-11-30 | Bristol-Myers Squibb Company | N-terminally modified GLP-1 receptor modulators |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
TW200726765A (en) * | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
WO2007002635A2 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
AU2006261828A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR20080034171A (ko) * | 2005-07-28 | 2008-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1h-피리도[4,3,b]인돌 |
EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
US7534804B2 (en) * | 2005-08-24 | 2009-05-19 | Bristol-Myers Squibb Company | Benzoxazole inhibitors of 15-lipoxygenase |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
WO2007027454A1 (en) * | 2005-08-30 | 2007-03-08 | Bristol-Myers Squibb Company | Heterocyclic dihydropyrimidine compounds |
ES2453981T3 (es) | 2005-08-31 | 2014-04-09 | University Of Tennessee Research Foundation | Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM) |
US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
EP1976873A2 (en) * | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
RU2435585C2 (ru) * | 2006-04-13 | 2011-12-10 | Актелион Фармасьютиклз Лтд | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких |
WO2007139589A1 (en) * | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
KR101460999B1 (ko) | 2006-07-12 | 2014-11-17 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
BRPI0714526A2 (pt) | 2006-08-24 | 2013-04-30 | Univ Tennessee Res Foundation | acilanilidas substituÍdas e seus mÉtodos de uso |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
CA2676066C (en) | 2007-01-22 | 2016-06-28 | Gtx, Inc. | Nuclear receptor binding agents |
TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
JP5309131B2 (ja) * | 2007-04-23 | 2013-10-09 | サノフイ | P2y12アンタゴニストとしてのキノリン−カルボキサミド誘導体 |
CN101668759A (zh) | 2007-05-04 | 2010-03-10 | 百时美施贵宝公司 | [6,5]-双环gpr119g蛋白-偶合受体激动剂 |
PE20090222A1 (es) * | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
CN101754972A (zh) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
PT2173737E (pt) | 2007-07-17 | 2012-03-19 | Bristol Myers Squibb Co | Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados |
WO2009018065A2 (en) * | 2007-07-27 | 2009-02-05 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
JP5504171B2 (ja) * | 2007-12-26 | 2014-05-28 | サノフイ | P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
EP2103602A1 (en) | 2008-03-17 | 2009-09-23 | AEterna Zentaris GmbH | Novel 1,2,4-triazole derivatives and process of manufacturing thereof |
EP2805939B1 (en) | 2008-05-19 | 2018-06-27 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as factor IXA inhibitors. |
PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
US20100256153A1 (en) | 2009-03-27 | 2010-10-07 | Bristol-Myers Squibb Company | Methods for preventing or reducing risk of mortality |
ES2769357T3 (es) | 2009-06-16 | 2020-06-25 | Pfizer | Formas farmacéuticas de apixaban |
EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
LT2498758T (lt) | 2009-11-13 | 2018-11-26 | Astrazeneca Ab | Dvisluoksnės tabletės formuluotės |
AU2010319438B2 (en) | 2009-11-13 | 2015-05-21 | Astrazeneca Uk Limited | Reduced mass metformin formulations |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
EA201270755A1 (ru) | 2010-04-08 | 2013-03-29 | Бристол-Майерс Сквибб Компани | Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119 |
EP2558461B1 (en) | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
WO2011140160A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
JP5705984B2 (ja) | 2010-08-23 | 2015-04-22 | ノバルティス アーゲー | Nep阻害剤を製造するための中間体の調製方法 |
EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
KR101458334B1 (ko) | 2010-12-23 | 2014-11-04 | 퍼듀 퍼머 엘피 | 탬퍼 저항성 고체 경구 투여 형태 |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
CA2853024C (en) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
CN104334557A (zh) | 2012-04-06 | 2015-02-04 | 辉瑞公司 | 二酰基甘油酰基转移酶2抑制剂 |
WO2013173198A1 (en) | 2012-05-16 | 2013-11-21 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
MY169219A (en) | 2012-06-11 | 2019-03-19 | Bristol Myers Squibb Co | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 ? sulfonamide |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
KR102122941B1 (ko) | 2012-07-13 | 2020-06-15 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9499482B2 (en) | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
WO2014039411A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
SG11201503923XA (en) | 2012-11-20 | 2015-06-29 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
CN105026399B (zh) | 2013-03-11 | 2017-06-23 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的吡咯并三嗪类化合物 |
EP2970199A1 (en) | 2013-03-11 | 2016-01-20 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
JP6386527B2 (ja) | 2013-03-11 | 2018-09-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カリウムイオンチャネル阻害剤としてのピロロピリダジン |
JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
US9580422B2 (en) | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
AU2015233094B2 (en) | 2014-03-17 | 2017-04-27 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
RS58597B1 (sr) | 2014-04-04 | 2019-05-31 | Pfizer | Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora |
EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
SG11201609050UA (en) | 2014-05-30 | 2016-12-29 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators |
WO2016103097A1 (en) | 2014-12-22 | 2016-06-30 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
PE20180503A1 (es) | 2015-05-05 | 2018-03-09 | Pfizer | 2-tiopirimidinonas |
JP2018516254A (ja) | 2015-05-29 | 2018-06-21 | ファイザー・インク | バニン1酵素の阻害薬としての新規なヘテロ環化合物 |
JP6827959B2 (ja) | 2015-06-17 | 2021-02-10 | ファイザー・インク | 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用 |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
BR112018002071A2 (pt) | 2015-08-13 | 2018-09-18 | Pfizer | compostos heteroarílicos ou arílicos fundidos bicíclicos |
SI3341367T1 (sl) | 2015-08-27 | 2021-05-31 | Pfizer Inc. | Biciklične kondenzirane heteroarilne ali arilne sestavine kot modulatorji IRAK-4 |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
ES2871251T3 (es) | 2015-12-29 | 2021-10-28 | Pfizer | 3-Azabiciclo[3.1.0]Hexanos sustituidos como inhibidores de la cetohexocinasa |
CA3030381A1 (en) | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
US10604541B2 (en) | 2016-07-22 | 2020-03-31 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
US20210169881A1 (en) | 2017-11-30 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
KR20210034039A (ko) | 2018-07-19 | 2021-03-29 | 아스트라제네카 아베 | 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물 |
MX2021002428A (es) | 2018-08-31 | 2023-01-02 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. |
WO2020068661A1 (en) | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
EP3972596A1 (en) | 2019-05-20 | 2022-03-30 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
EP3990452A1 (en) | 2019-06-28 | 2022-05-04 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022554277A (ja) | 2019-10-30 | 2022-12-28 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
CN115103842A (zh) | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | 用于治疗眼部疾病的组合物 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
PE20231215A1 (es) | 2020-06-09 | 2023-08-17 | Pfizer | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
CA3218251A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024084390A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the activation of ampk |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB804036A (en) * | 1956-03-02 | 1958-11-05 | Hoffmann La Roche | A process for the manufacture of a sulphanilamide of the isoxazole series |
US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
DE1059459B (de) * | 1956-09-04 | 1959-06-18 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wertvollen 3-Sulfanilamido-5-methylisoxazols |
CH364506A (de) * | 1956-09-04 | 1962-09-30 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wirksamen 3-Sulfanilamido-5-methyl-isoxazols |
GB897440A (en) * | 1960-02-08 | 1962-05-30 | Shionogi & Co | Improvements in or relating to sulfonamides |
GB1473433A (ja) * | 1975-10-09 | 1977-05-11 | Banyu Pharmaceutical Co Ltd Hi | |
US4415496A (en) * | 1981-03-23 | 1983-11-15 | Merck & Co., Inc. | Bicyclic lactams |
DE3276313D1 (en) * | 1981-09-24 | 1987-06-19 | Beecham Wuelfing Gmbh & Co Kg | Sulphonamides |
US4661479A (en) * | 1982-02-19 | 1987-04-28 | Merck And Co., Inc. | Bicyclic lactams as antihypertensives |
EP0194548A3 (de) * | 1985-03-12 | 1988-08-17 | Dr. Karl Thomae GmbH | Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
CA2005741C (en) * | 1988-12-26 | 1998-06-02 | Hiroyoshi Hidaka | Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity |
US5082838A (en) * | 1989-06-21 | 1992-01-21 | Takeda Chemical Industries, Ltd. | Sulfur-containing fused pyrimidine derivatives, their production and use |
DE19675036I2 (de) * | 1990-02-19 | 2004-10-21 | Novartis Ag | Acylverbindungen. |
CA2079343A1 (en) * | 1990-03-30 | 1991-10-01 | Eric E. Allen | Substituted pyrazoles, isoxazoles and isothiazoles |
US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
TW270116B (ja) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
CZ287406B6 (cs) * | 1991-11-05 | 2000-11-15 | Smithkline Beecham Corporation | Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
SE9103397D0 (sv) * | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
TW224462B (ja) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
TW215434B (ja) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
AU4376893A (en) * | 1992-05-19 | 1993-12-13 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
TW287160B (ja) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
EP0617001B1 (en) * | 1993-03-19 | 2000-01-26 | Merck & Co. Inc. | Phenoxyphenylacetic acid derivatives |
CA2121724A1 (en) * | 1993-04-21 | 1994-10-22 | Toshifumi Watanabe | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
DE59409631D1 (de) * | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
DE19509950A1 (de) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
CZ299246B6 (cs) * | 1995-04-04 | 2008-05-28 | Encysive Pharmaceuticals Inc. | Sulfonamid, farmaceutická kompozice s jeho obsahem a jeho použití pro výrobu léciva |
UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
-
1998
- 1998-01-23 TW TW087101072A patent/TW536540B/zh active
- 1998-01-26 JP JP53299998A patent/JP2002513397A/ja not_active Ceased
- 1998-01-26 DE DE69819729T patent/DE69819729T2/de not_active Expired - Lifetime
- 1998-01-26 CZ CZ992362A patent/CZ236299A3/cs unknown
- 1998-01-26 WO PCT/US1998/001490 patent/WO1998033780A1/en not_active Application Discontinuation
- 1998-01-26 EP EP98906005A patent/EP0996618B1/en not_active Expired - Lifetime
- 1998-01-26 CN CN98802096A patent/CN1117738C/zh not_active Expired - Fee Related
- 1998-01-26 AT AT98906005T patent/ATE254115T1/de active
- 1998-01-26 IL IL13062298A patent/IL130622A/xx not_active IP Right Cessation
- 1998-01-26 AU AU61349/98A patent/AU730111B2/en not_active Ceased
- 1998-01-26 BR BR9807098-3A patent/BR9807098A/pt not_active IP Right Cessation
- 1998-01-26 HU HU0001310A patent/HUP0001310A3/hu unknown
- 1998-01-26 RU RU99118903/04A patent/RU2183632C2/ru not_active IP Right Cessation
- 1998-01-26 CA CA002279178A patent/CA2279178A1/en not_active Abandoned
- 1998-01-26 NZ NZ336380A patent/NZ336380A/en unknown
- 1998-01-26 KR KR1019997006831A patent/KR20000070584A/ko not_active Application Discontinuation
- 1998-01-26 ES ES98906005T patent/ES2205451T3/es not_active Expired - Lifetime
- 1998-01-26 PL PL98334773A patent/PL334773A1/xx unknown
- 1998-01-27 US US09/013,952 patent/US6043265A/en not_active Expired - Lifetime
- 1998-01-29 ZA ZA9800759A patent/ZA98759B/xx unknown
- 1998-01-30 AR ARP980100427A patent/AR015358A1/es not_active Application Discontinuation
-
1999
- 1999-07-29 NO NO19993691A patent/NO313142B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016504286A (ja) * | 2012-11-14 | 2016-02-12 | バイアル−ポルテラ アンド シーエー,エス.エー. | 肺動脈高血圧症及び肺障害の治療に使用するための1,3‐ジヒドロイミダゾール‐2‐チオン誘導体 |
US10308640B2 (en) | 2012-11-14 | 2019-06-04 | Bial-Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
WO2022270487A1 (ja) * | 2021-06-22 | 2022-12-29 | 株式会社アークメディスン | 化合物、エンドセリンa受容体拮抗剤及び医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
IL130622A (en) | 2003-01-12 |
BR9807098A (pt) | 2000-04-18 |
AU6134998A (en) | 1998-08-25 |
DE69819729D1 (de) | 2003-12-18 |
KR20000070584A (ko) | 2000-11-25 |
NO993691L (no) | 1999-07-29 |
WO1998033780A1 (en) | 1998-08-06 |
NZ336380A (en) | 2001-04-27 |
IL130622A0 (en) | 2000-06-01 |
AR015358A1 (es) | 2001-05-02 |
CZ236299A3 (cs) | 1999-11-17 |
ATE254115T1 (de) | 2003-11-15 |
NO993691D0 (no) | 1999-07-29 |
RU2183632C2 (ru) | 2002-06-20 |
EP0996618A4 (en) | 2000-05-03 |
EP0996618B1 (en) | 2003-11-12 |
TW536540B (en) | 2003-06-11 |
DE69819729T2 (de) | 2004-09-23 |
AU730111B2 (en) | 2001-02-22 |
HUP0001310A2 (hu) | 2001-06-28 |
HUP0001310A3 (en) | 2001-07-30 |
NO313142B1 (no) | 2002-08-19 |
CN1244862A (zh) | 2000-02-16 |
US6043265A (en) | 2000-03-28 |
CA2279178A1 (en) | 1998-08-06 |
ZA98759B (en) | 1999-07-29 |
EP0996618A1 (en) | 2000-05-03 |
PL334773A1 (en) | 2000-03-13 |
ES2205451T3 (es) | 2004-05-01 |
CN1117738C (zh) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002513397A (ja) | エンドセリン拮抗薬:n−〔〔2’−〔〔(4,5−ジメチル−3−イソキサゾリル)アミノ〕スルホニル〕−4−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−イル〕メチル〕−n,3,3−トリメチルブタンアミドおよびn−(4,5−ジメチル−3−イソキサゾリル)−2’−〔(3,3−ジメチル−2−オキソ−1−ピロリジニル)メチル〕−4’−(2−オキサゾリル)〔1,1’−ビフェニル〕−2−スルホンアミドおよびそれらの塩 | |
RU2141953C1 (ru) | Сульфамидные соединения или их фармацевтически пригодные соли и способ ингибирования рецепторов ета | |
RU2159770C2 (ru) | Замещенные бифенилсульфонамиды, фармацевтическая композиция на их основе, способ антагонистического воздействия на эндотелин | |
JPH09124620A (ja) | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 | |
WO2017041701A1 (zh) | 可释放一氧化氮的前药分子 | |
JP6965390B2 (ja) | フマレート類似体および自己免疫疾患または炎症性疾患の治療におけるその使用 | |
PL183283B1 (pl) | Nowe podstawione bifenyloizoksazolosulfonamidy i środek farmaceutyczny | |
JP2007506770A (ja) | 線溶系の障害および血栓症の治療用のpai−1阻害剤としての、4−(1h−インドール−3−イル−メチリデンアミノキシ−プロポキシ)−安息香酸誘導体および関連化合物 | |
WO2019169193A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
KR102351418B1 (ko) | 1-(3-메틸-2-옥소-2,3-디히드로-1,3-벤족사졸-6-일)-2,4-디옥소-3-[(1r)-4-(트리플루오르메틸)-2,3-디히드로-1h-인덴-1-일]-1,2,3,4-테트라히드로피리미딘-5-카르복실산의 염 | |
WO2018214872A1 (zh) | 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途 | |
JP2019504084A (ja) | Nrf2活性化化合物およびその使用 | |
CA2707095A1 (en) | Phenyl-oxetanyl-derivatives | |
WO2016034103A1 (zh) | 取代的四氢噻吩并吡啶衍生物及其应用 | |
TW201629040A (zh) | 新穎化合物 | |
JPH02229168A (ja) | ピラゾロン誘導体 | |
JP3387948B2 (ja) | 新規なフェニルアラニン誘導体またはその塩 | |
JPH02229169A (ja) | ピラゾロン誘導体 | |
WO2021036495A1 (zh) | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 | |
WO2024036961A1 (zh) | 一种抗衰老相关疾病的前药及其使用方法 | |
JP2002540088A (ja) | ビフェニルイソキサゾール・スルホンアミド化合物の製造法 | |
JPH08509487A (ja) | シクロオキシゲナーゼ及び5−リポキシゲナーゼを阻害するヒドロキサム酸誘導体 | |
CN114751874A (zh) | 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用 | |
WO2012136121A1 (zh) | 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080826 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090401 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |